EliteImmune

EliteImmune is a private, pre-clinical stage biotech company operating at the intersection of immunology and cell therapy. It employs a hybrid business model, combining internal therapeutic development with external contract research services through its 'EliteImmune BioServices' division. The company's core strategy is to use its proprietary platforms to discover and develop novel antibody therapeutics against infectious diseases while generating early revenue through reagent sales and funded research services.

Proprietary CellProbe™ and CellSeq™ platforms for high-throughput identification, isolation, and sequencing of antibody-producing B cells, enabling rapid discovery of fully human antibodies.

EliteImmune competes with numerous biotech firms offering antibody discovery platforms (e.g., AbCellera, Distributed Bio) and large pharma with internal capabilities. Its differentiation hinges on the efficiency and output quality of its integrated CellProbe™/CellSeq™ system and its focused application to infectious disease targets.